A clinic nurse is reviewing the pre-procedure checklist for a client scheduled for a bronchoscopy with a potential biopsy. Which finding requires immediate communication with the healthcare provider?

An INR of 3.5 indicates significant coagulopathy, posing high bleeding risk during bronchoscopy with biopsy. Other findings like mild hypertension, tachycardia, or low-grade fever are manageable and do not require immediate communication.

Understanding the Clinical Scenario
A bronchoscopy with potential biopsy is an invasive procedure that carries a risk of bleeding, particularly if tissue samples are taken. The pre-procedure nursing checklist is designed to identify and mitigate risks. While vital sign variations can be important, the most critical finding here relates to coagulation status, as an unrecognized coagulopathy can lead to a life-threatening hemorrhage during or after the procedure.

Analysis of the Options
Let's examine each finding in the context of procedural safety.

1. Blood pressure: 148/92 mmHg
This reading indicates Stage 1 hypertension. While it is a finding that should be documented and monitored, it is not an absolute contraindication to a bronchoscopy. The procedure can often proceed safely with this level of blood pressure, especially if the client has a history of hypertension. It does not pose the same immediate, life-threatening procedural risk as a severe coagulopathy.

2. Heart rate of 98 beats per minute
A heart rate of 98 bpm is within the upper limit of the normal adult range (60-100 bpm). A mildly elevated heart rate can be due to anxiety, pain, or mild dehydration. This finding requires assessment but does not necessitate immediate cancellation or communication with the provider as a critical safety alert.

3. Temperature of 99.2°F (37.3°C)
This is a low-grade temperature elevation. While a significant fever might indicate an active infection that could postpone an elective procedure, a temperature of 99.2°F is not a definitive sign of a systemic infection that would warrant immediate cancellation. It is a finding to note, but it is not the highest priority.

4. International normalized ratio (INR) of 3.5
This is the critical finding. A therapeutic INR for most indications is between 2.0 and 3.0. An INR of 3.5 is supratherapeutic, indicating a significantly prolonged clotting time and a high risk for spontaneous and procedure-related bleeding. For a procedure with a high bleeding risk like a bronchoscopy with biopsy, the target INR is typically much lower, often less than 1.5. This value requires immediate communication with the healthcare provider, as the procedure will likely need to be postponed and the anticoagulation regimen adjusted.

Deep Dive: Why the INR is the Priority
The core of this question lies in balancing the risk of a thromboembolic event against the risk of a hemorrhagic complication, a concept directly addressed in the provided evidence. A review on the perioperative management of oral anticoagulants highlights that the temporary discontinuation and restarting of these medications for invasive procedures must be meticulously designed “both to reduce thromboembolic events and to avoid hemorrhagic complications” . An INR of 3.5 represents a state where the hemorrhagic risk far outweighs any potential thrombotic protection during an invasive biopsy.

The specific danger of bleeding during a bronchoscopic biopsy is starkly illustrated by the condition known as Bronchial Dieulafoy's disease (BDD). Although rare, BDD is a vascular malformation characterized by aberrant, large submucosal arteries that can cause “life-threatening hemorrhage” if biopsied . This risk is so profound that a “biopsy-sparing bronchoscopic approach” is recommended when typical endoscopic signs are visualized, with management shifting to arterial embolization instead of tissue sampling . While the question does not suggest the client has BDD, it powerfully underscores why any coagulopathy, such as an elevated INR, must be corrected before a bronchoscopic biopsy. The combination of an invasive biopsy in a highly vascular airway and a supratherapeutic INR creates a perfect storm for a catastrophic bleed.

Furthermore, a study on lung biopsies in immunocompromised patients reminds us that while these procedures are valuable, they carry inherent “complication rates” . The nurse’s role in the pre-procedure checklist is to act as a safety barrier, identifying factors like an INR of 3.5 that would exponentially increase those baseline complication rates. This is not a simple out-of-range value; it is a direct contraindication to proceeding safely. The nurse must recognize that the risk of a major hemorrhagic complication from the biopsy in this scenario is imminent and preventable only by immediate communication and intervention.